Breaking News, Collaborations & Alliances

BMS, Allergan in Pain Pact

BMS, Allergan to co-develop Phase II-ready neuropathic pain compound

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Bristol-Myers Squibb and Allergan have entered a global agreement for the development and commercialization of AGN-209323, a Phase II-ready, orally administered small molecule in clinical development for neuropathic pain. BMS will gain exclusive worldwide rights to develop, manufacture and commercialize AGN-209323 and backup compounds. The agreement encompasses all potential indications, except ophthalmology indications for products formulated for local delivery to the eye, for which Allergan...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters